智通财经APP获悉,根据周二发表的研究报告,辉瑞(PFE.US)的乳腺癌药物Ibrance(也被称为palbociclib)在治疗某种类型的阑尾癌方面显示出令人鼓舞的效果。
研究表明,Ibrance能够稳定腹膜粘液癌患者的肿瘤生长并降低血液肿瘤标志物水平。这种癌症很罕见,通常对标准化疗有抗药性。
这项研究还表明,Ibrance能够减缓或阻止癌细胞的增殖。研究人员补充说,下一步是用化疗和靶向药物治疗来测试这种药物,看看它的有效性是否可以增强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.